California Code of Regulations › Title 8 - Industrial Relations › Division 1 - Department of Industrial Relations › Chapter 4 - Division of Industrial Safety › Subchapter 7 - General Industry Safety Orders › Group 16 - Control of Hazardous Substances › Article 110 - Regulated Carcinogens › Appendix C to Section 5200 - Medical Surveillance Guidelines for MDA

Current through Register 2024 Notice Reg. No. 28, July 12, 2024
I. ROUTE OF ENTRY
Inhalation; skin absorption; ingestion. MDA can be
						  inhaled, absorbed through the skin, or ingested.
II. TOXICOLOGY
MDA is a suspect carcinogen in humans. There are
						  several reports of liver disease in humans and animals resulting from acute
						  exposure to MDA. A well documented case of an acute cardiomyopathy secondary to
						  exposure to MDA is on record. Numerous human cases of hepatitis secondary to
						  MDA are known. Upon direct contact MDA may also cause damage to the eyes.
						  Dermatitis and skin sensitization have been observed. Almost all forms of acute
						  environmental hepatic injury in humans involve the hepatic parenchyma and
						  produce hepatocellular jaundice. This agent produces intrahepatic cholestasis.
						  The clinical picture consists of cholestatic jaundice, preceded or accompanied
						  by abdominal pain, fever, and chills. Onset in about 60% of all observed cases
						  is abrupt with severe abdominal pain. In about 30% of observed cases, the
						  illness presented and evolved more slowly and less dramatically, with only
						  slight abdominal pain. In about 10% of the cases only jaundice was evident. The
						  cholestatic nature of the jaundice is evident in the prominence of itching, the
						  histologic predominance of bile stasis, and portal inflammatory infiltration,
						  accompanied by only slight parenchmal injury in most cases, and by the
						  moderately elevated transaminase values. Acute, high doses, however, have been
						  known to cause hepatocellular damage resulting in elevated SGPT, SGOT, alkaline
						  phosphatase and bilirubin.
Absorption through the skin is rapid. MDA is
						  metabolized and excreted over a 48-hour period. Direct contact may be
						  irritating to the skin, causing dermatitis. Also MDA which is deposited on the
						  skin is not thoroughly removed through washing.
MDA may cause bladder cancer in humans. Animal data
						  supporting this assumption is not available nor is conclusive human data.
						  However, human data collected on workers at a helicopter manufacturing facility
						  where MDA is used suggests a higher incidence of bladder cancer among exposed
						  workers.
III. SIGNS AND SYMPTOMS
Skin may become yellow from contact with MDA. Repeated
						  or prolonged contact with MDA may result in recurring dermatitis (red- itchy,
						  cracked skin) and eye irritation. Inhalation, ingestion or absorption through
						  the skin at high concentrations may result in hepatitis, causing symptoms such
						  as fever and chills, nausea and vomiting, dark urine, anorexia, rash, right
						  upper quadrant pain and jaundice. Corneal burns may occur when MDA is splashed
						  in the eyes.
IV. TREATMENT OF ACUTE TOXIC EFFECTS/EMERGENCY
						  SITUATION
If MDA gets into the eyes, immediately wash eyes with
						  large amounts of water. If MDA is splashed on the skin, immediately wash
						  contaminated skin with mild soap or detergent. Employee should be removed from
						  exposure and given proper medical treatment. Medical tests required under the
						  emergency section of the medical surveillance subsection (m)(4) must be
						  conducted.
If the chemical is swallowed do not induce vomiting but
						  remove by gastric lavage.